Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EPS (Basic) (2018 - 2025)

Inmune Bio's EPS (Basic) history spans 8 years, with the latest figure at -$0.2 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 66.67% year-over-year to -$0.2; the TTM value through Sep 2025 reached -$2.08, up 4.59%, while the annual FY2024 figure was -$2.11, 26.35% down from the prior year.
  • EPS (Basic) for Q3 2025 was -$0.2 at Inmune Bio, up from -$1.05 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.2 in Q3 2025 and bottomed at -$1.05 in Q2 2025.
  • The 5-year median for EPS (Basic) is -$0.43 (2022), against an average of -$0.47.
  • The largest annual shift saw EPS (Basic) crashed 124.99% in 2021 before it soared 66.67% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.55 in 2021, then soared by 41.82% to -$0.32 in 2022, then tumbled by 46.87% to -$0.47 in 2023, then grew by 14.89% to -$0.4 in 2024, then soared by 50.0% to -$0.2 in 2025.
  • Per Business Quant, the three most recent readings for INMB's EPS (Basic) are -$0.2 (Q3 2025), -$1.05 (Q2 2025), and -$0.43 (Q1 2025).